Citations

Clear

16281 citation(s) found for "Yu, David".

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Jensen, Jeffrey L. , Bobek, Olivia , Chan, Irenaeus C.C. , Miller, Brian C. , Hillman, David W. , Heller, Glenn , Druley, Todd E. , Armstrong, Andrew J. , Morris, Michael J. , Milowsky, Matthew I. , Beltran, Himisha , Coombs, Catherine C. , Druley, Todd , Bolton, Kelly L , Coombs, Catherine C , Morris, Michael J , Hillman, David W , Heller, Glenn , Bobek, Olivia , Armstrong, Andrew J , Bolton, Kelly L.

Mayo Clinic

Clinical Cancer Research | September 17, 2024 | Volume: 30 | Issue: 21 | Pages: 4910-4919

10.1158/1078-0432.ccr-24-0803 | PMID 39287426 Get It

Abstract Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (OS), predominantly through cardiovascular adverse events (CVAE). Because androgen receptor pathway inhibitors (ARPI) used in metastatic castration-resistant prostate cancer (mCRPC) are also associated with CVAEs and because CH negatively impacted survival in an advanced solid tumor cohort, we hypothesized that CH in mCRPC may be associated with increased CVAEs and inferior survival. Experimental Design: A targeted DNA sequencing panel captured common CH mutations in pretreatment blood samples from 957 patients enrolled in Alliance A031201: a randomized trial of enzalutamide ± abiraterone/prednisone in the first-line mCRPC setting. The primary outcome was the impact of CH on OS; the secondary outcomes were progression-free survival (PFS) and CVAEs. Results: Baseline comorbidities were similar by CH status. No differences in OS/progression-free survival were detected regardless of treatment arm or the variant allele frequency threshold used to define CH [primary: 2% (normal-CH, N-CH); exploratory: 0.5% (low-CH) and 10% (high-CH, H-CH)]. Patients with H-CH (7.2%) and TET2-mutated N-CH (6.0%) had greater odds of any CVAE (14.5% vs. 4.0%; P = 0.0004 and 12.3% vs. 4.2%; P = 0.010, respectively). More major CVAEs were observed in patients with H-CH (5.8% vs. 1.9%; P = 0.042) and N-CH (3.4% vs. 1.8%; P = 0.147). Conclusions: CH did not affect survival in patients with mCRPC treated with ARPIs in A031201. H-CH and TET2-mutated CH were associated with more CVAEs. These findings inform the risk/benefit discussion about ARPIs in mCRPC.
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine
Tepper, Stewart J. , Doležil, David, Gil‐Gouveia, Raquel , Lucas, Christian , Piasecka‐Stryczynska, Karolina , Mikol, Daniel D., Chehrenama, Mahan, Chou, Denise E. , Yang, Yiping, Lima, Gabriel Paiva da Silva , Lima, Gabriel Paiva da Silva , Dodick, David W. , Lantéri‐Minet, Michel , Szabó, Gyöngyi

Mayo Clinic

JAMA Neurology | September 16, 2024 | Volume: 81 | Issue: 11 | Pages: 1140

10.1001/jamaneurol.2024.3043 | PMID 39283627 Get It

ImportancePatients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in CM-MOH.ObjectiveTo assess erenumab efficacy and safety in patients with nonopioid CM-MOH.Design, Settings, and ParticipantsThis randomized, double-blind, parallel-group, placebo-controlled trial took place at 67 centers in North America, Europe, and Australia from October 7, 2019, to November 2, 2022. This report reflects the primary analysis conducted in January 2023, using a database snapshot from December 1, 2022, which contains the complete dataset of the double-blind treatment period (DBTP). Participants included adults with CM-MOH who had 1 or more preventive treatment failure(s). There were 992 participants screened and 620 participants enrolled (584 in nonopioid cohort and 36 in opioid cohort)InterventionsErenumab, 70 mg, 140 mg, or placebo, once monthly for 24 weeks.Main Outcomes and MeasuresThe primary end point was MOH remission at month 6. Secondary end points included change from baseline in mean monthly acute headache medication days (AHMD) at month 6 and sustained MOH remission throughout the DBTP. Safety end points were adverse events and changes in vital signs.ResultsThe primary analysis population included 584 participants in the nonopioid-treated cohort with a mean age of 44 years and 482 participants were female (82.5%). Baseline demographics and disease characteristics were balanced across groups. At month 6, 134 participants in the erenumab, 140 mg group (69.1%) (odds ratio [OR], 2.01; 95% CI, 1.33-3.05; P < .001 vs placebo) and 117 in the erenumab, 70 mg group (60.3%) (OR, 1.37; 95% CI, 0.92-2.05; P = .13 vs placebo) achieved MOH remission vs 102 participants in the placebo group (52.6%). AHMD use was also reduced in the erenumab groups vs placebo. Least squares mean (standard error) change from baseline in average monthly AHMD was –9.4 (0.4) days in the erenumab, 140 mg group (difference from placebo, –2.7; 95% CI, –3.9 to –1.6; P < .001) and –7.8 (0.4) days in the erenumab, 70 mg group (difference from placebo, –1.2; 95% CI, –2.4 to –0.1; P = .03), vs –6.6 (0.4) days in the placebo group. MOH remission throughout the DBTP was sustained in 119 participants (61.3%,) 96 participants (49.5%), and 73 participants (37.6%) in the erenumab, 140 mg, 70 mg, and placebo groups, respectively. Adverse events were consistent with the known safety profile of erenumab. Treatment-emergent adverse events incidence in the combined erenumab group was 66.8% (259 participants; constipation 15.2% (59 participants) and COVID-19 13.9% (54 participants) were most common.Conclusions and RelevanceIn this study, monthly, 140 mg, erenumab injections safely and effectively achieved MOH remission in patients with nonopioid CM-MOH within 6 months.Trial RegistrationClinicalTrials.gov Identifier: NCT03971071
Impact Of Creatine Supplement And Doxorubicin Therapy On Creatine Kinase Expression In Skeletal Muscle
Sharif, Salaheddin, Olson, Thomas P. , Hydock, David S.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2024 | Volume: 56 | Issue: 10S | Pages: 914-915

10.1249/01.mss.0001060532.36726.b0 Get It

The Role of Cardiovascular Imaging in the Diagnosis of Athlete’s Heart: Navigating the Shades of Grey
Ali, Nima Baba , Esfahani, Sogol Attaripour , Scalia, Isabel G. , Farina, Juan M. , Pereyra, Milagros , Barry, Timothy , Lester, Steven J., Alsidawi, Said , Steidley, D. Eric , Ayoub, Chadi , Palermi, Stefano , Arsanjani, Reza , Baba Ali, Nima , Attaripour Esfahani, Sogol, Steidley, David E, Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Alsidawi, Said , Scalia, Isabel G

Mayo Clinic

Journal of Imaging | September 16, 2024 | Volume: 10 | Issue: 9 | Pages: 230

10.3390/jimaging10090230 | PMID 39330450 Get It

Athlete’s heart (AH) represents the heart’s remarkable ability to adapt structurally and functionally to prolonged and intensive athletic training. Characterized by increased left ventricular (LV) wall thickness, enlarged cardiac chambers, and augmented cardiac mass, AH typically maintains or enhances systolic and diastolic functions. Despite the positive health implications, these adaptations can obscure the difference between benign physiological changes and early manifestations of cardiac pathologies such as dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic cardiomyopathy (ACM). This article reviews the imaging characteristics of AH across various modalities, emphasizing echocardiography, cardiac magnetic resonance (CMR), and cardiac computed tomography as primary tools for evaluating cardiac function and distinguishing physiological adaptations from pathological conditions. The findings highlight the need for precise diagnostic criteria and advanced imaging techniques to ensure accurate differentiation, preventing misdiagnosis and its associated risks, such as sudden cardiac death (SCD). Understanding these adaptations and employing the appropriate imaging methods are crucial for athletes’ effective management and health optimization.
Efficacy and safety of flow diverters in retreatment of recurrent intracranial aneurysms—A systematic review and meta-analysis
Zarrintan, Armin , Ghozy, Sherief , Maroufi, Seyed Farzad , Reda, Abdullah, Brinjikji, Waleed , Kadirvel, Ramanathan , Kallmes, David F. , Gajjar, Aryan , Ghozy, Sherief , Zarrintan, Armin

Mayo Clinic

Interventional Neuroradiology | September 14, 2024 | Volume: 32 | Issue: 4 | Pages: 1729-1740

10.1177/15910199241282713 | PMID 39275854 Get It

Background and purpose Treatment of recurrent intracranial aneurysms after their initial therapy has been a significant challenge in the field of neurointervention. Recently flow diverters stents are widely used for treating intracranial aneurysms. In this systematic review and meta-analysis, we assessed the safety and efficacy of flow diverter in treating recurrent or recanalized intracranial aneurysms. Methods This meta-analysis is reported following the PRISMA 2020 guidelines. We conducted a systematic review of literature in the PubMed, Embase, Web of Sciences, and Scopus databases. Pooled prevalence and the corresponding 95% are calculated from extracted data using a random-effect model. Results The systematic literature search included 21 studies involving 411 patients, with 135 (32.8%) being male and 276 (67.2%) being females with a total number of 447 aneurysms. The overall rate of adequate occlusion was 90.67% (95% CI: 84.23%–94.65%), and the rates were comparable between the surgery (93.48%), coiling (91.78%), and stenting (85.77%) groups. The overall pooled rate of complete occlusion was 81.80 (95% CI: 71.14%–89.13%). On doing a subgroup analysis, the complete occlusion rates were 89.68%, 84.39%, and 73.47% for the surgery, coiling, and stenting groups, respectively. The overall mortality rate and achieving modified Rankin scale score of 0-2 was 1.28% (95% CI: 0.45%–3.64%) and (95% CI: 89.92%–97.84%), respectively. No significant heterogeneity is noted in the included studies. Conclusion Flow diverter stents are an effective and safe method for retreating recurrent or residual intracranial aneurysms with a high rate of complete and adequate occlusion. The rate of mortality, intracerebral hemorrhage, and overall and procedural complications following using flow diverters for intracranial aneurysms is low.
Predictive value of follow-up infarct volume on functional outcomes in middle cerebral artery M2 segment vessel occlusion stroke treated with mechanical thrombectomy
Yedavalli, Vivek, Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Kühn, Anna Luisa, Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Barreau, Xavier, Renieri, Leonardo, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Essibayi, Muhammed Amir , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Colasurdo, Marco , Salim, Hamza , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Essibayi, Muhammed Amir , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Yedavalli, Vivek S , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Puri, Ajit S , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | September 14, 2024 | Volume: 10 | Issue: 2 | Pages: 431-441

10.1177/23969873241275531 | PMID 39269154 Get It

Abstract Background: Medium vessel occlusion (MeVO) strokes, particularly affecting the M2 segment of the middle cerebral artery, represent a critical proportion of acute ischemic strokes, posing significant challenges in management and outcome prediction. The efficacy of mechanical thrombectomy (MT) in MeVO stroke may warrant reliable predictors of functional outcomes. This study aimed to investigate the prognostic value of follow-up infarct volume (FIV) for predicting 90-day functional outcomes in MeVO stroke patients undergoing MT. Methods: This multicenter, retrospective cohort study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, covering patients with acute ischemic stroke due to M2 segment occlusion treated with MT. We examined the relationship between 90-day functional outcomes, measured by the modified Rankin Scale (mRS), and follow-up infarct volume (FIV), assessed through CT or MRI within 12–36 h post-MT. Results: Among 130 participants, specific FIV thresholds were identified with high specificity and sensitivity for predicting outcomes. A FIV ⩽5 ml was highly specific for predicting favorable and excellent outcomes. The optimal cut-off for both prognostications was identified at ⩽15 ml by the Youden Index, with significant reductions in the likelihood of favorable outcomes observed above a 40 ml threshold. Receiver Operator Curve (ROC) analyses confirmed FIV as a superior predictor of functional outcomes compared to traditional recanalization scores, such as final modified thrombolysis in cerebral infarction score (mTICI). Multivariable analysis further highlighted the inverse relationship between FIV and positive functional outcomes. Conclusions: FIV within 36 h post-MT serves as a potent predictor of 90-day functional outcomes in patients with M2 segment MeVO strokes. Establishing FIV thresholds may aid in the prognostication of stroke outcomes, suggesting a role for FIV in guiding post intervention treatment decisions and informing clinical practice. Future research should focus on validating these findings across diverse patient populations and exploring the integration of FIV measurements with other clinical and imaging markers to enhance outcome prediction accuracy.
The effect of intravenous thrombolysis in stroke patients with unsuccessful thrombectomy
Elawady, Sameh Samir , Kasem, Rahim Abo , Sowlat, Mohamed Mahdi, Nawabi, Noah, Venegas, Joshua M. , Isidor, Julio , Loulida, Hasna , Maier, Ilko , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Kan, Peter, Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kasab, Sami Al , Venegas, Joshua M , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Altschul, David J , Crosa, Roberto , Abo Kasem, Rahim , Matsukawa, Hidetoshi , Cunningham, Conor M. , Orscelik, Atakan , Jabbour, Pascal , Rai, Ansaar , Samaniego, Edgar A , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Matouk, Charles , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De

Mayo Clinic

Interventional Neuroradiology | September 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241279009 | PMID 39262342 Get It

Background The benefit of intravenous thrombolysis (IVT) is well established. We aim to study the benefits of IVT in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) who underwent unsuccessful mechanical thrombectomy (MT). Methods We included AIS patients who underwent MT for anterior circulation LVO with failed recanalization (modified treatment in cerebral ischemia [mTICI] score ≤ 2A). Patients who received IVT prior to MT were compared to those who received MT alone. Propensity score matching using demographic, clinical, radiographic and procedural variables was used to match patients with and without IVT. The primary outcome was favorable 90-day good functional outcome (defined as modified Rankin scale of 0–2), and secondary outcomes included intracranial hemorrhage (ICH), symptomatic ICH (sICH), and 90-day mortality. Results Totally, 610 AIS patients with unsuccessful MT were included. After propensity matching, 219 patients were identified in each group. Median age was 70 years and 73 years in the IVT + MT and MT alone groups, respectively. In the IVT + MT group, final mTICI scores of 0, 1, and 2A were achieved in 92 (42.0%), 33 (15.1%), and 94 (42.9%) patients, respectively, versus 76 (34.7%), 29 (13.2%), and 114 (52.1%) in the MT alone group. The IVT + MT group had greater odds of 90-day good functional outcome (adjusted odds ratio 2.54, 95% confidence interval 1.53–4.32). There were no significant differences in secondary outcomes. Conclusions IVT is associated with improved functional outcomes in AIS patients with LVO despite unsuccessful MT.